Optimization of a synthetic beta-catenin-dependent promoter for tumor-specific cancer gene therapy.

@article{Lipinski2004OptimizationOA,
  title={Optimization of a synthetic beta-catenin-dependent promoter for tumor-specific cancer gene therapy.},
  author={Kai S. Lipinski and Hakim A Djeha and Jonathan M. Gawn and Suzanne Cliffe and Norman J. Maitland and Daniel H. Palmer and Andrew Mountain and Alistair S. Irvine and Christopher J. Wrighton},
  journal={Molecular therapy : the journal of the American Society of Gene Therapy},
  year={2004},
  volume={10 1},
  pages={150-61}
}
We recently published the construction and evaluation of a beta-catenin-dependent, highly active promoter, CTP1, and its possible application for the treatment of colorectal cancer using gene-directed enzyme prodrug therapy with adenoviral (Ad) vectors. Alternative Ad-based approaches such as tumor-specific, replication-competent vectors and/or exploiting therapeutic gene products with intrinsic toxic activity, such as gibbon ape leukemia virus fusogenic membrane glycoprotein, diphtheria toxin… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 14 extracted citations

Similar Papers

Loading similar papers…